Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila maintains an Overweight rating on Monte Rosa Therapeutics (NASDAQ:GLUE) but lowers the price target from $18 to $17.
August 12, 2024 | 5:40 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wells Fargo analyst Derek Archila maintains an Overweight rating on Monte Rosa Therapeutics but lowers the price target from $18 to $17.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100